Clarity Pharmaceuticals (ASX:CU6) said it achieved the target number of participants for its phase 3 Amplify trial for copper-64-SAR-bisPSMA positron emission tomography in participants with rising or detectable prostate-specific antigen (PSA) after initial definitive treatment, according to a Tuesday ASX filing.

The study, which will enroll 220 participants, seeks to investigate the diagnostic ability of copper-64-SAR-bisPSMA positron emission tomography/computed tomography to detect the recurrence of prostate cancer in men with PSA levels above 0.2 nanograms per milliliter.

Consenting of new patients stopped at all sites pending the completion of the remaining screening assessments and confirmation of final enrollment numbers, the filing said.

The company's shares rose past 2% in recent trading on Tuesday.